Biocon Joins Fray For Denosumab, Ustekinumab Biosimilars

Eylea Biosimilar Option Exercised

 
• By Anju Ghangurde
  
Generate a summary of this article
Listen to this article
Beta

Biocon is progressing trials for biosimilar rivals to Amgen’s Prolia/Xgeva (denosumab) and J&J’s Stelara (ustekinumab), even as it gears for other large opportunities coming its way via the Viatris deal including for blockbusters Humira and Eylea.

partnering
Biocon Projects Robust Growth Outlook • Source: Alamy

Biocon expects to build on portfolio gains and commercial capabilities in developed markets via the Viatris biosimilars transaction, with its vaccines alliance with Serum Institute of India driving new growth opportunities alongside. Two “unpartnered” assets - denosumab and ustekinumab biosimilars – have also moved into clinical trials, expanding pipeline promise.

Kiran Mazumdar-Shaw, chairperson, Biocon and Biocon Biologics, said that continued improvement in the performance of the existing portfolio, coupled with...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.